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Summary 
The concurrent targeting of critical nodes along key signaling pathways with molecularly 
targeted agents is a rational antitumor strategy, which has had varying degrees of 
success. Combinatorial challenges include overcoming synergistic toxicities and 
establishing if combinations are truly active, to make “go, no-go” decisions to proceed to 
later phase trials. 
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In this issue of Clinical Cancer Research, Calvo and colleagues report a phase I trial 
combining dacomitinib, the small molecule irreversible pan-HER inhibitor and 
figitumumab, the insulin growth factor-1 receptor (IGF-1R) monoclonal antibody (1). 
Significant signaling crosstalk exists between the pan-HER family of receptor tyrosine 
kinase (TKI) pathways and IGF signaling network; therefore, combinatorial targeting of 
critical nodes along these pathways are a rational antitumor strategy (2) (Figure 1). 
There has been much hope placed on the development of rational combination 
regimens of molecularly targeted agents against key signaling pathways to overcome 
treatment resistance observed with single agent therapies (3). While we have had 
evidence of success with such targeted combinations, e.g. blockade of BRAF and MEK 
in BRAF V600E mutant melanoma (4), a major challenge has been synergistic toxicities 
observed with a number of targeted combinations, especially those involving the 
horizontal blockade of parallel signaling pathways (Figure 1). These toxicities have 
often hindered dose escalation of one or both drugs to single agent recommended 
phase 2 doses (RP2D), potentially resulting in the administration of subtherapeutic 
doses of either or both drugs, likely leading to poor pharmacokinetic exposures and lack 
of target modulation. A potential strategy around this may be to alter drug scheduling, 
e.g. with pulsatile dosing of one or both drugs to reduce such toxicities. 
 
With regards to the study by Calvo and colleagues, this was essentially a dose de-
escalation study, despite investigators starting dacomitinib and figitumumab at 
reasonable doses, which were below the RP2D of both drugs (1). However, dose-
limiting toxicities (DLTs) and chronic intolerance prevented monotherapy RP2Ds of both 
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drugs from being reached. With the benefit of hindsight, this increased rate of serious 
toxicities should not be surprising, given the findings observed in the phase 3 trial of the 
epidermal growth factor receptor (EGFR) TKI erlotinib in combination with figitumumab 
in patients with non-adenocarcinoma non-small cell lung cancer (NSCLC). This 
combination failed to demonstrate a survival benefit, and significantly increased 
toxicities in the combination arm (5). Another issue with targeted combinations is the 
seemingly mild chronic toxicities, which are often not taken into consideration when 
establishing the RP2D as they do not constitute DLTs during phase I studies. However, 
such chronic adverse events have been found to lead to dose reductions and 
interruptions in phase 3 studies, potentially affecting the efficacy and regulatory 
approval of such drugs (6).  
 
In this study, it is unclear if this is a truly synergistic combination of two drugs known to 
be active as monotherapies. Overall, antitumor activity was modest, with only 3 
objective responses observed out of 61 evaluable patients, despite the investigators 
enriching the patient population with cancers known to respond to both drugs as single 
agents. Two of the three RECIST partial responses were also observed at intolerable 
doses of the combination (1). Furthermore, while suboptimal doses of pan-HER 
blockade may, in theory, interact favorably with IGF-1R inhibition to lead to responses, it 
is likely that the antitumor activity observed in these three patients were due to 
figitumumab, rather than dacomitinib or the combination since the doses of dacomitinib 
given to these responders were well below its monotherapy RP2D (1). Remarkably, the 
preclinical gene set enrichment studies suggested that low, rather than high, levels of 
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the target of figitumumab were associated with greater levels of tumor growth delay. 
Indeed, higher levels of IGF-1R pathway activation were associated with non-response. 
Although the authors suggested that this paradox might represent a “saturation effect”, 
this observation certainly deserves more detailed analysis before embarking on larger 
studies.  
 
It now seems like an age-old debate – and remains a continued challenge - how one 
actually determines, in phase I studies, if a combination potentially has superior 
antitumor activity to either single agent, so as to make robust “go, no-go” decisions to 
proceed to later phase trials (3). This is particularly relevant when one or both drugs are 
known to be potentially efficacious – as is the case with this trial - since it will be 
challenging to assess the synergistic value of the combination without a large and 
suitably powered randomized trial. Although a randomized phase 2 trial would seem like 
the ideal next step, such a study may be associated with high false-positive and/or 
false-negative rates, complicating interpretation of the results. A more novel strategy 
involves a “reversal-of-resistance” approach, where patients are initially exposed to one 
drug (usually the active one) until disease progression, when the second drug is added 
to assess if drug resistance is “reversed” (3).  
 
Aligning clinical and pre-clinical drug testing in co-clinical trials is an emerging strategy 
for early drug development and appears to be a sound approach to explore adaptive 
therapies aimed at overcoming drug resistance, especially in rare tumor types (7). The 
authors used avatar mouse models of adenoid cystic carcinoma (ACC) to explore the 
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synergic effects of figitumumab and dacomitinib. The results from these avatar studies 
were expressed as percentage tumor growth inhibition relative to control, without data 
provided on absolute tumor volumes and their changes over time, making it difficult to 
interpret these data and draw inferences on the relative roles of the two agents in 
mediating the observed therapeutic effects. Regardless, there appears to be little 
synergistic activity between the two drugs since the tumor growth inhibition achieved 
with the combination is comparable to single agent figitumumab in most of the patient-
derived xenografts (PDXs).  
 
It would have been interesting if tumor specimens for PDXs and molecular profiling had 
been obtained at baseline and at disease progression from patients with ACC enrolled 
in the trial, instead of an independent cohort, so as to add biological insights into the 
development of predictive biomarkers of response. While obtaining sequential biopsies 
from phase I trial patients poses potential safety, logistical and ethical issues, they 
represent an opportunity to define changes in the molecular profile of the tumor during 
treatment, so as to dissect mechanisms of synergy and to influence decision-making in 
proceeding to phase II trials. Organoid technologies have made rapid advances in 
recent years (8), and may represent a cost-effective alternative to genetically-
engineered mouse models and PDXs, providing a timely and financially sustainable 
platform to understand tumor heterogeneity, predict resistance mechanisms, and enable 
high-throughput drug discovery. 
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Both dacomitinib and figitumumab were developed with relatively high expectations, but 
have unfortunately not found their niche areas of unmet need to achieve regulatory 
approval (9,10).  Pfizer has discontinued figitumumab development, while dacomitinib is 
currently being assessed in a phase III trial versus gefinitib (AstraZeneca) for the first 
line treatment of advanced EGFR mutant NSCLC. However, in a rapidly evolving and 
crowded treatment landscape in EGFR mutant NSCLC, even if this is a positive trial and 
dacomitinib is approved, its role in this space remains unclear given its toxicity profile 
and potential fiscal burden (11). 
 
Ultimately, with some combinations, it may simply not be feasible to block two or more 
key signaling pathways involved in critical malignant and normal cellular functions. In 
such situations, one should consider a sequential rather than concurrent use of such 
agents, as guided by molecular profiling of tumor re-biopsies or circulating tumor DNA 
(12). Finally, in the advent of immuno-oncology and the emergence of novel epigenetic 
inhibitors, one should also widen the spectrum of rational combination regimens to 
include other exciting classes of antitumor agents. 
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FIGURE LEGEND 
Figure 1.  Combination studies of molecularly targeted agents against critical 
targets along the IGF-1R and HER family signaling pathways. 
The combination of inhibitors against RAF and MEK along the MAPK signaling pathway 
is now Food and Drug Administration (FDA)-approved for clinical application (green 
line). Several other combinations have successfully completed phase I/II trials, 
suggesting that these regimens are potentially feasible with early signals of 
antitumor responses observed (orange lines). However, other combinations have been 
found to be intolerable in phase I trials (solid red lines), or have failed to meet their 
endpoints of survival or response in phase II/III studies (dotted red lines). While this list 
of combinations - based on peer-reviewed publications and/or international conference 
abstracts - is not exhaustive, it does suggest that combining molecularly targeted 
therapies against critical targets along these key signaling pathways is fraught with 
potential pitfalls and challenges. Nevertheless, there has been evidence of success, 
providing proof-of-concept for this antitumor strategy. Combination approaches 
involving other classes of antitumor agents, e.g. angiogenesis and DNA repair, are also 
currently being explored (not shown in figure).   
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